Klion Amy
Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA.
Annu Rev Med. 2009;60:293-306. doi: 10.1146/annurev.med.60.062107.090340.
Hypereosinophilic syndrome is a heterogeneous group of rare disorders characterized by marked blood or tissue eosinophilia resulting in a wide variety of clinical manifestations. Although the existence of clinical subtypes (or variants) of HES has been appreciated for some time, the recent characterization of some of these variants at the molecular and immunologic levels has demonstrated dramatic differences in disease pathogenesis, response to treatment, and prognosis depending on the etiology of the eosinophilia. This, together with the availability of novel targeted therapies, including tyrosine kinase inhibitors and monoclonal antibodies, has fundamentally altered the approach to the diagnosis and treatment of HES.
高嗜酸性粒细胞综合征是一组异质性罕见疾病，其特征为血液或组织中嗜酸性粒细胞显著增多，从而导致多种多样的临床表现。尽管一段时间以来人们已经认识到高嗜酸性粒细胞综合征存在临床亚型（或变异型），但最近在分子和免疫水平对其中一些变异型的特征描述表明，根据嗜酸性粒细胞增多的病因不同，疾病的发病机制、对治疗的反应及预后存在显著差异。这一点，再加上新型靶向治疗药物的出现，包括酪氨酸激酶抑制剂和单克隆抗体，已从根本上改变了高嗜酸性粒细胞综合征的诊断和治疗方法。
